Your Compounding Questions Answered

Martin A. Erickson III, RPh
Published Online: Monday, July 15, 2013
Follow Pharmacy_Times:
Q: I have a prescription for cidofovir cream for a pediatric patient’s wart. What vehicle and concentration should I use?

A: Cidofovir (Vistide, Gilead) was approved for treatment of cytomegalovirus retinitis in patients with AIDS in 1996. Its mechanism of action is suppression of cytomegalovirus replication by selective inhibition of viral DNA synthesis. It was not approved for other indications; this question concerns an off-label use. Chemically, cidofovir is an acyclic nucleoside phosphonate and therefore does not require phosphorylation by viral enzymes for its activity, as acyclovir does. It is nephrotoxic and therefore carries precautions against use in patients with impaired renal function and who are receiving therapy with other nephrotoxic drugs. Gupta M et al reported topical treatment of verrucae with cidofovir cream in 12 children (Topical cidofovir for refractory verrucae in children [published online September 26, 2012]. Pediatr Dermatol. 2013; 30[1]:131-134. doi: 10.1111/j.1525-1470.2012.01798.x. Epub 2012 Sep 26.). In this report, 7 patients exhibited partial to complete clearing of the treated verrucae when cidofovir in moisturizing cream was applied every other day at concentrations of 1% to 3%. The authors speculated that the low concentrations of cidofovir used might have led to the mediocre results. In other studies, patients have exhibited complete to partial clearing of anogenital papillomavirus lesions when treated with cidofovir.

Cidofovir is mutagenic: any preparations should be compounded using OSHA HAZMAT precautions (closed-front gown, gloves, mask, Class II biologic safety cabinet); recommended disposal of contaminated materials is high-temperature incineration.

Suggested topical preparation:
  • Cidofovir 5%
  • Cold cream (without)  *100% as needed
    * Eucerin (Boehringer Ingelheim); Almonderm (Fagron US).
Suggested preparation method:
  1. Weigh/measure components accurately.
  2. Using geometric dilution technique, levigate the cidofovir into a small amount of propylene glycol or the cold cream to make a paste.
  3. Geometrically combine the paste in (2) with the cold cream until completely mixed. (If an Unguator is used to mix the material, use disposable blades, etc.)
  4. Label appropriately, and dispense with precautions about contact with healthy skin.
  5. Keep refrigerated up to 30 days (USP<795>).

Mr. Erickson is director of professional affairs and director of professional services at Gallipot, a Fagron company.

Related Articles
Patients with bipolar disorder and other mental illnesses are more likely to be tested for human immunodeficiency virus.
Mylan, Inc, announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc, under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide as both a single agent product and in combination with other drugs.
Gilead Sciences Inc. has reported positive results from its phase 2 and phase 3 studies on ledipasvir 90 mg/sofosbuvir 400 mg in patients with chronic hepatitis C virus.
Gilead Sciences, Inc., has submitted a new drug application to the FDA for its investigational single-tablet regimen for HIV infection in adult patients.
Latest Issues